Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 13 min ago
Peer-reviewedCC BY 4.0Frontiers in Oncology

Epithelial-mesenchymal transition plasticity in breast cancer: regulatory mechanisms and therapeutic implications

  • Chunlei Wang1,2
  • Jie Cao1,2
  • Bo Qin1,2
  1. 1Shaoxing Maternity and Child Health Care Hospital
  2. 2Maternity and Child Health Care Affiliated Hospital, Shaoxing University
Read full textPDFDOICite

Abstract

Metastatic dissemination and therapeutic failure, the major determinants of breast cancer mortality, are fundamentally driven by epithelial-mesenchymal transition (EMT) and its phenotypic plasticity. This review comprehensively interrogates the regulatory logic of EMT plasticity in breast cancer, decoding the intricate interplay among transcription factor cascades, epigenetic landscapes, non-coding RNA circuits, and microenvironmental cues that collectively sustain tumor cell adaptability. We further delineate the translational frontier, summarizing recent advances in pharmacologically targeting EMT core regulators and discussing the promise and pitfalls of plasticity-modulating therapeutic paradigms. Ultimately, by integrating evolving knowledge from basic and translational research, we present a cohesive framework aimed at bridging mechanistic understanding with clinical decision-making, with the goal of refining precision therapy for breast cancer patients.

Related

  1. From inflammation to carcinogenesis: MiRNA regulates epithelial-mesenchymal transition to facilitate malignant progression of gastric precancerous lesions
    Yibing Tian, Tai Zhang, Bochao Yuan +3
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  2. Isoliquiritigenin inhibits TGF-β1-induced epithelial–mesenchymal transition in pulmonary fibrosis by promoting Nix-mediated mitophagy
    Shaorui Ke, Tiantian Liu, Qin Hu +4
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textEpidemiology & public healthCrossref
  3. UCHL1 Promotes Epithelial–Mesenchymal Transition Through E-Cadherin and N-Cadherin Switch in Endometrial Cancer
    Azusa Kobayashi, Kohshiro Nakao, Naoki Inoue +5
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Integrative Multi-Omics Reveals TSPAN13 as a Candidate Epithelial–Mesenchymal Transition-Associated Regulator in Prostate Cancer
    Shuo Lu, Houhe Li, Zixiao Zhang +6
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Keratin 17 Defines an Epithelial-Mesenchymal Transition-Associated Migratory Cell State in Pancreatic Ductal Adenocarcinoma
    Shayan Sarkar, Monisankar Ghosh, Lyanne Delgado-Coka +10
    bioRxivPreprintAll rights reservedFull textOncologybioRxivPMC

Cite

BibTeXRIS
BibTeX
@article{wang2026epithelialmesenchymal,
  title = {{Epithelial-mesenchymal transition plasticity in breast cancer: regulatory mechanisms and therapeutic implications}},
  author = {Chunlei Wang and Jie Cao and Bo Qin},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1959152},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1959152/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Epithelial-mesenchymal transition plasticity in breast cancer: regulatory mechanisms and therapeutic implications
AU  - Chunlei Wang
AU  - Jie Cao
AU  - Bo Qin
PY  - 2026
DA  - 2026/10/14
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1959152
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1959152/full
AB  - Metastatic dissemination and therapeutic failure, the major determinants of breast cancer mortality, are fundamentally driven by epithelial-mesenchymal transition (EMT) and its phenotypic plasticity. This review comprehensively interrogates the regulatory logic of EMT plasticity in breast cancer, decoding the intricate interplay among transcription factor cascades, epigenetic landscapes, non-coding RNA circuits, and microenvironmental cues that collectively sustain tumor cell adaptability. We further delineate the translational frontier, summarizing recent advances in pharmacologically targeting EMT core regulators and discussing the promise and pitfalls of plasticity-modulating therapeutic paradigms. Ultimately, by integrating evolving knowledge from basic and translational research, we present a cohesive framework aimed at bridging mechanistic understanding with clinical decision-making, with the goal of refining precision therapy for breast cancer patients.
SN  - 2234-943X
ER  -